Fat mass and obesity-associated protein (FTO) mediates signal transducer and activator of transcription 3 (STAT3)-drived resistance of breast cancer to doxorubicin

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. DOI:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2019;69(5):363–385.
   PubMed Web of Science ®Google Scholar
• Chen J, Du B. Novel positioning from obesity to cancer: FTO, an m(6)A RNA demethylase, regulates tumour progression. J Cancer Res Clin Oncol. 2019;145(1):19–29.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wan Y, Zhang Z, et al. FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway. RNA Biol. 2020;1–14. DOI:10.1080/15476286.2020.1841458
   Web of Science ®Google Scholar
• Zhao L, Kong X, Zhong W, et al. FTO accelerates ovarian cancer cell growth by promoting proliferation, inhibiting apoptosis, and activating autophagy. Pathol Res Pract. 2020;216(9):153042.
   PubMed Web of Science ®Google Scholar
• Tang X, Liu S, Chen D, et al. The role of the fat mass and obesity-associated protein in the proliferation of pancreatic cancer cells. Oncol Lett. 2019;17(2):2473–2478.
   PubMed Web of Science ®Google Scholar
• Liu J, Ren D, Du Z, et al. m(6)A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. Biochem Biophys Res Commun. 2018;502(4):456–464.
   PubMed Web of Science ®Google Scholar
• Yang S, Wei J, Cui YH, et al. m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10(1):2782.
   PubMed Web of Science ®Google Scholar
• Li Z, Weng H, Su R, et al. FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. Cancer Cell. 2017;31(1):127–141.
   PubMed Web of Science ®Google Scholar
• Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer. 2019;18(1):46.
   PubMed Web of Science ®Google Scholar
• Tan A, Dang Y, Chen G, et al. Overexpression of the fat mass and obesity associated gene (FTO) in breast cancer and its clinical implications. Int J Clin Exp Pathol. 2015;8(10):13405–13410.
   PubMed Web of Science ®Google Scholar
• Gelain A, Mori M, Meneghetti F, et al. Signal Transducer and Activator of Transcription Protein 3 (STAT3): an Update on its Direct Inhibitors as Promising Anticancer Agents. Curr Med Chem. 2019;26(27):5165–5206.
   PubMed Web of Science ®Google Scholar
• Guo C, Yang G, Khun K, et al. Activation of Stat3 in renal tumors. Am J Transl Res. 2009;1(3):283–290.
   PubMed Web of Science ®Google Scholar
• Tian F, Yang X, Liu Y, et al. Constitutive activated STAT3 is an essential regulator and therapeutic target in esophageal squamous cell carcinoma. Oncotarget. 2017;8(51):88719–88729.
   PubMedGoogle Scholar
• Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004;103(8):3175–3184.
   PubMed Web of Science ®Google Scholar
• Dhir R, Ni Z, Lou W, et al. Stat3 activation in prostatic carcinomas. Prostate. 2002;51(4):241–246.
   PubMed Web of Science ®Google Scholar
• Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138(11):2570–2578.
   PubMed Web of Science ®Google Scholar
• Gu D, Fan Q, Zhang X, et al. A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis. J Biol Chem. 2012;287(45):38356–38366.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhu S, Shen M, et al. STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1. Carcinogenesis. 2013;34(3):678–688.
   PubMed Web of Science ®Google Scholar
• Gariboldi MB, Ravizza R, Molteni R, et al. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 2007;258(2):181–188.
   PubMed Web of Science ®Google Scholar
• Lin L, Hutzen B, Zuo M, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010;70(6):2445–2454.
   PubMed Web of Science ®Google Scholar
• Real PJ, Sierra A, De Juan A, et al. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002;21(50):7611–7618.
   PubMed Web of Science ®Google Scholar
• Bravard A, Vial G, Chauvin MA, et al. FTO contributes to hepatic metabolism regulation through regulation of leptin action and STAT3 signalling in liver. Cell Commun Signal. 2014;12(1):4.
   PubMed Web of Science ®Google Scholar
• Wu R, Guo G, Bi Z, et al. m(6)A methylation modulates adipogenesis through JAK2-STAT3-C/EBPbeta signaling. Biochim Biophys Acta Gene Regul Mech. 2019;1862(8):796–806.
   PubMed Web of Science ®Google Scholar
• Luo J, Zeng S, Tian C. MORC4 Promotes Chemoresistance of Luminal A/B Breast Cancer via STAT3-Mediated MID2 Upregulation. Onco Targets Ther. 2020;13:6795–6803.
   PubMed Web of Science ®Google Scholar
• Marinello PC, Panis C, Silva TNX, et al. Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. Sci Rep. 2019;9(1):5864.
   PubMed Web of Science ®Google Scholar
• Cole MP, Todd ID, Wilkinson PM. A preliminary trial of doxorubicin in advanced breast cancer and other malignant disease. Br J Cancer. 1974;29(2):114–116.
   PubMed Web of Science ®Google Scholar
• Han J, Lim W, You D, et al. Chemoresistance in the human triple-negative breast cancer cell line MDA-MB-231 Induced by doxorubicin gradient is associated with epigenetic alterations in histone deacetylase. J Oncol. 2019:1345026 2019. 10.1155/2019/1345026
   PubMed Web of Science ®Google Scholar
• Bravard A, Lefai E, Meugnier E, et al. FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction. Diabetes. 2011;60(1):258–268.
   PubMed Web of Science ®Google Scholar
• Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894.
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng D, Wang F, et al. Expression of demethylase genes, FTO and ALKBH1, is associated with prognosis of gastric Cancer. Dig Dis Sci. 2019;64(6):1503–1513.
   PubMed Web of Science ®Google Scholar
• Strick A, Von Hagen F, Gundert L, et al. The N(6) -methyladenosine (m(6) A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma. BJU Int. 2020;125(4):617–624.
   PubMed Web of Science ®Google Scholar
• Xu D, Shao W, Jiang Y, et al. FTO expression is associated with the occurrence of gastric cancer and prognosis. Oncol Rep. 2017;38(4):2285–2292.
   PubMed Web of Science ®Google Scholar
• Xu Y, Ye S, Zhang N, et al. The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. Cancer Commun (Lond). 2020;40(10):484–500.
   PubMed Web of Science ®Google Scholar
• Zou D, Dong L, Li C, et al. The m(6)A eraser FTO facilitates proliferation and migration of human cervical cancer cells. Cancer Cell Int. 2019;19(1):321.
   PubMed Web of Science ®Google Scholar
• Zhou S, Bai ZL, Xia D, et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting beta-catenin through mRNA demethylation. Mol Carcinog. 2018;57(5):590–597.
   PubMed Web of Science ®Google Scholar
• Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling. Cell. 2018;172(1–2):90–105 e123.
   PubMed Web of Science ®Google Scholar
• Avalle L, Camporeale A, Camperi A, et al. STAT3 in cancer: a double edged sword. Cytokine. 2017;98:42–50.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhu Y, Yue Y, et al. Tamoxifen attenuates reactive astrocyte-induced brain metastasis and drug resistance through the IL-6/STAT3 signaling pathway. Acta Biochim Biophys Sin (Shanghai). 2020;52(12):1299–1305.
   PubMed Web of Science ®Google Scholar
• Lo HW, Hsu SC, Ali-Seyed M, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 2005;7(6):575–589.
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Matsumoto S, Masuda J, et al. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res. 2007;27(6A):3749–3756.
   PubMed Web of Science ®Google Scholar
• Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20(20):2499–2513.
   PubMed Web of Science ®Google Scholar